S

    Sonoma Pharmaceuticals Inc (SNOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.31
    -0.02 (-1.50%)

    Market Cap: $6.27M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(18/30)
    Avg Surprise
    +34.12%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$0.02N/AN/ABeat+105.4%
    Mar 26
    		$-0.15N/AN/ABeat+68.7%
    Dec 25
    		$-0.48$-0.29-65.52%Miss+23.8%
    Sep 25
    		$-0.32$-0.31-3.23%Miss+45.8%
    Jun 25
    		$-0.37$-0.51+27.45%Beat+73.6%
    Mar 25
    		$-0.48$-0.04-1100.00%Miss-585.7%
    Dec 24
    		$-0.63$-0.60-5.00%Miss+60.6%
    Sep 24
    		$-0.59$-0.80+26.25%Beat+89.8%
    Jun 24
    		$-1.40$-0.80-75.00%Miss-400.7%
    Mar 24
    		$-0.07N/A+58.82%Beat+77.4%
    Dec 23
    		$-1.60N/A+61.90%Beat-158.1%
    Sep 23
    		$-5.80$-4.80-20.83%Miss-1657.6%
    Jun 23
    		$-0.28$-0.12-133.00%Miss+3.6%
    Mar 23
    		$-0.31$-0.23-34.78%Miss+0.0%
    Dec 22
    		$-0.62$-0.62+0.00%Beat-1450.0%
    Sep 22
    		$-0.33$0.00N/ABeat+36.5%
    Jun 22
    		$-0.29$0.00N/ABeat+44.7%
    Dec 21
    		$-0.31$0.00N/ABeat+3.1%
    Sep 21
    		$-0.04$0.00N/ABeat-166.7%
    Jun 21
    		$-0.52$0.00N/ABeat-196.3%
    Mar 21
    		$-0.52$0.00N/AMiss-36.1%
    Dec 20
    		$-0.32N/A+55.56%Beat-102.5%
    Sep 20
    		$0.06N/A+105.08%Beat+100.3%
    Jun 20
    		$0.54$-0.91+159.34%Beat+102.0%
    Mar 20
    		$-0.39$0.00N/ABeat+74.6%
    Dec 19
    		$12.72$-0.72+1866.67%Beat+127.2%
    Sep 19
    		$-18.20$-23.60+22.88%Beat+77.0%
    Jun 19
    		$-26.70$-35.80+25.42%Beat+73.0%
    Mar 19
    		$-1.52$-2.12+28.30%Beat+81.8%
    Dec 18
    		$-46.80$-60.30+22.39%Beat+64.4%
    Sep 18
    		$-79.20$-81.90+3.30%Beat+34.3%
    Jun 18
    		$-99.00$-95.40-3.77%Miss+32.9%
    Mar 18
    		$-8.37$-5.28-58.52%Miss-63.2%
    Dec 17
    		$-131.40$-111.00-18.38%Miss-117.8%
    Sep 17
    		$-120.60$-124.20+2.90%Beat-89.3%
    Jun 17
    		$-147.60$-131.40-12.33%Miss-
    Mar 17
    		$-5.13$-6.03+14.93%Beat-
    Dec 16
    		$736.56$554.40+32.86%Beat-
    Sep 16
    		$-63.72$-106.20+40.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.41EV/EBITDA11.46x
    Price/FCF-1.90xFCF Yield-52.70%
    Profitability
    Profit Margin-10.30%Operating Margin-0.62%
    ROE-42.50%ROIC-33.62%
    Financial Health
    Debt/Equity0.02xInterest Coverage-2.28x
    Current Ratio2.99xQuick Ratio2.29x
    Trading Statistics
    Beta1.29Avg Volume223.49K
    52-Week High$4.7752-Week Low$0.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.34
    SMA 20$1.31
    SMA 50$1.23
    SMA 200$2.21
    EMA 10$1.33
    EMA 20$1.31
    EMA 50$1.29
    EMA 200$1.97

    MACD

    Line: 0.03Signal: 0.04Hist: -0.00

    ADX

    ADX: 32.1+DI: 19.8-DI: 11.4

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down24.0
    PSAR$1.45

    Bollinger Bands

    Upper Band$1.47
    Lower Band$1.15
    %B Position2448%(Upper)
    Band Width0.50

    RSI (14-Day)

    Neutral
    52.2

    Momentum Oscillators

    Stoch %K48.2
    Stoch %D58.6
    Williams %R-73.3
    ROC (10d)0.8%
    Momentum0.01
    CCI (20d)16.9
    MFI (14d)37.1

    Volatility Measures

    ATR (14d)$0.08(6.0%)
    StdDev (20d)0.08
    Hist Vol90.7%(High)

    Volume Flow

    VWAP$1.32
    OBV224.1M
    AD Line-58.9M
    CMF (20d)0.228

    Volume Metrics

    Avg Vol (20d)243.5K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.32

    Pivot Points

    R3$1.45
    R2$1.42
    R1$1.38
    Pivot Point$1.35
    S1$1.31
    S2$1.28
    S3$1.24

    Advanced Oscillators

    TSI12.64
    Ultimate Osc45.4
    KST120.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.41M$5.56M$4.35M$5.60M$4.01M$3.75M$3.56M$3.58M$3.39M$3.44M$3.14M$2.73M
    Cost of Revenue$3.83M$3.38M$2.70M$3.48M$2.55M$2.23M$2.29M$2.22M$2.08M$2.35M$1.68M$1.74M
    Gross Profit$2.58M$2.18M$1.65M$2.12M$1.46M$1.53M$1.27M$1.36M$1.31M$1.09M$1.46M$990,000
    Operating Expenses$2.62M$2.53M$2.33M$2.46M$2.56M$2.18M$2.30M$2.21M$2.48M$2.50M$2.30M$2.20M
    R&D$597,000$545,000$557,000$575,000$594,000$411,000$427,000$506,000$470,000$409,000$601,000$536,000
    SG&A$2.02M$1.99M$1.77M$1.88M$1.97M$1.77M$1.87M$1.71M$2.01M$2.09M$1.70M$1.66M
    Operating Income$-40,000$-351,000$-678,000$-337,000$-1,095,000$-656,000$-1,031,000$-850,000$-1,173,000$-1,409,000$-844,000$-1,208,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$290,000$146,000$271,000$394,000$147,000$0$0$0$0$0$79,000$90,000
    Income Before Tax$-330,000$-497,000$-949,000$-731,000$-1,242,000$-528,000$-919,000$-463,000$-997,000$-1,359,000$-923,000$-1,298,000
    Income Tax Expense$0$84,000$-130,000$-197,000$-1,000$248,000$9,000$147,000$146,000$-292,000$-57,000$186,000
    Net Income$-330,000$-581,000$-819,000$-534,000$-1,241,000$-776,000$-928,000$-610,000$-1,143,000$-1,067,000$-866,000$-1,484,000
    EBITDA$-298,000$-464,000$-915,000$-695,000$-1,206,000$-497,000$-886,000$-428,000$-958,000$-1,318,000$-878,000$-1,253,000
    EBIT$-330,000$-497,000$-949,000$-731,000$-1,242,000$-528,000$-919,000$-463,000$-997,000$-1,359,000$-923,000$-1,298,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNOA

    News

    Price to book forward of Sonoma Pharmaceuticals, Inc. – MUN:O8Z

    This article provides financial data for Sonoma Pharmaceuticals, Inc. (MUN:O8Z) focusing on its price-to-book forward ratio. It appears to be a data point from TradingView, which offers various market tools and financial information. The content primarily lists navigation and site-related information rather than a detailed analysis.

    TradingView•8/22/26•
    Neutral

    Sonoma Pharmaceuticals cancels special meeting due to lack of quorum

    Sonoma Pharmaceuticals (NASDAQ:SNOA) announced the cancellation of its adjourned special meeting of stockholders because a quorum was not reached. The meeting, which was intended to address matters detailed in a proxy statement from May 5, 2026, required the presence of holders of one-third of the company's common stock, which was not met. Separately, the company recently received FDA 510(k) clearance for its Microdacyn Wound Irrigation Solution and increased its at-the-market equity program to $3.64 million.

    Investing.com•8/20/26•
    Somewhat-Bearish

    Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com

    Sonoma Pharmaceuticals announced the cancellation of its adjourned special meeting of stockholders due to a lack of quorum, as not enough shareholders participated to meet the required threshold. The meeting was originally called to address matters detailed in a proxy statement from May 2026. Separately, the company recently received FDA clearance for its Microdacyn Wound Irrigation Solution and increased its at-the-market equity program to $3.64 million.

    Investing.com South Africa•8/19/26•
    Neutral

    Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com

    This article reports that Sonoma Pharmaceuticals Inc. filed a Form 8K on August 19. The article provides only this brief announcement and includes market data, news headlines, and stock performance figures for various companies and indices. It does not elaborate on the specific content of the 8K filing.

    Investing.com Nigeria•8/19/26•
    Neutral

    Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com

    This article reports on the filing of a Form 8K by Sonoma Pharmaceuticals Inc. on August 19th. The content is brief, primarily serving as an announcement of the SEC filing for the company. Sonoma Pharmaceuticals Inc. (SNOA) saw a stock increase of 4.62% as of the report.

    Investing.com Canada•8/19/26•
    Neutral

    Frequently Asked Questions About SNOA

    Does SNOA pay dividends?
    Sonoma Pharmaceuticals Inc (SNOA) does not currently pay a regular dividend.
    What is SNOA's market cap?
    Sonoma Pharmaceuticals Inc (SNOA) has a market capitalization of $6.27M with a current stock price of $1.31.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In